Skip to content
GLP-1 Scorecard
Menu
Graded #80

Pallas Health

Compounded semaglutide and tirzepatide sold only on a twelve-week prepay — there is no month-to-month rung, so the advertised "$199/mo average" is a $597 charge divided by three.

Visit Pallas HealthWe may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Semaglutide
$199/mo average ($597 billed every 12 weeks; $139 first 4 weeks)
Tirzepatide
$299/mo average ($897 billed every 12 weeks; $179 first 4 weeks)
Coverage
All 50 states plus Washington, D.C.
Brand-name
Yes

Weigh Pallas Health against the full graded field on the best semaglutide providers scorecard, or line it up against its closest alternatives.

Factor breakdown

Each of the six graded dimensions. See the methodology.

Cost value55/100
Dose & formulation76/100
Clinical oversight84/100
Labs & monitoring52/100
Fulfillment86/100
Contract terms68/100

Strengths

  • Names six dispensing pharmacies outright on a public page — Belmar, Strive, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub and Foothills — and explains the 503A versus 503B distinction alongside them. Almost nothing else on this board names one at all
  • Two prescribing physicians are named with their NPI numbers and a "verify in the NPPES registry" link: Dr. Ana Lisa Carr, MD (NPI 1689841744, licensed in 15 states) and Dr. Kelly Tenbrink, MD (NPI 1346482684, licensed in Tennessee and Florida). Both resolve to active NPPES records
  • LegitScript Healthcare Merchant certified (seal 49989444), and the FDA's warning-letter index carries nothing against Pallas Health, its operator Brentmoor, Inc., or the CareValidate platform it runs on
  • The marketing price is the checkout price — the homepage FAQ, the landing pages, the treatment pages and the live funnel all state the same figures, and no step-up appears at the payment screen
  • Cancelling is self-serve and free with no minimum term: a portal at pallashealth.co/portal, an email reminder before each renewal, at least 30 days' notice before any price change, and a full refund if a clinician declines you
  • All 50 states and Washington, D.C., asynchronous in 43 of them, FSA/HSA eligible per the site banner, free shipping when prescribed — plus a brand-name lane (Zepbound, Ozempic, Wegovy, Mounjaro) that is genuinely billed monthly

Where it loses points

  • There is no month-to-month rung for either compounded molecule — the funnel renders no cadence selector at all. After $139 for the first four weeks the second charge is $597, in one go, four weeks later; on tirzepatide it is $179 and then $897
  • Twelve weeks is not three months. The renewal recurs every 84 days — 4.348 times a year, not 4 — while the advertised average divides one twelve-week prepay by 3. On Pallas's own published renewal terms the steady state is $2,596/yr (about $216/mo) on semaglutide and $3,900/yr (about $325/mo) on tirzepatide: roughly 8.7% above the advertised averages
  • $139 and $179 are first-period rates only, and the sitewide "Up to $120 off your first month" banner is a discount, not a price
  • Whether baseline or follow-up lab work is included or costs extra is not published anywhere, and there is no pre-purchase dose selector — so whether the price rises with dose, beyond the flat claim, is not published either
  • Only two clinicians are named site-wide, and the footer's "Provider directory" link resolves to the section naming those same two. The actual prescribing network — Lion MD's affiliated professional corporations — is not published. NPPES confirms Dr. Carr's family-medicine taxonomy; the obesity and addiction medicine board certifications the site claims for her are not verifiable through NPPES and we did not check them independently
  • One of the six named dispensing pharmacies, Belmar, received an FDA warning letter issued March 2023 over compounding practices, addressed to "Belmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy" — which the FDA CLOSED OUT in October 2023. It is a disclosure about a supplier; Pallas Health carries no warning letter of its own
  • The compounded semaglutide and tirzepatide are not FDA-approved and are not generic equivalents of Wegovy or Zepbound. Pallas discloses this properly, but it still bounds what the medication is
  • No insurance, ever. The brand-name lane runs $1,069/mo for Zepbound up to $1,349/mo for Wegovy and Mounjaro, cash — far above what an insured patient pays for the same product
  • $5 is deducted from each refunded payment on purchases made on or after 14 July 2026 (never on a clinician-declined or unfulfilled order, which refund in full). In the seven states that require a video visit — Arkansas, Mississippi, New Mexico, North Dakota, Rhode Island, South Dakota, West Virginia — plus Washington, D.C., a $60 visit deposit can be retained if you neither attend nor reschedule and then abandon the intake
  • The site's own footer states that "Some content on this site is AI-generated; no representation or warranty is made regarding its accuracy, completeness, or reliability" — so its blog is not a source for a clinical claim. The advertised "4.8" rating has no published source, and the before/after "Verified Customer" stories carry a note that the individuals shown may be actors or models
  • New here — first tracked in July 2026 — with no Trustpilot or BBB record published to cross-check it against

Bottom line — Grade C

Best for: Readers who can absorb a $597 or $897 charge every twelve weeks, and who want the dispensing pharmacies and the prescribing physicians named before they hand over a card.

Ranked #80 of 506 on this scorecard. See our top-scoring pick, CoreAge Rx (#1), for comparison.

Closest on the board

The boards grading nearest Pallas Health — the realistic shortlist.

The 24 boards nearest this one

View full scorecard rankings →

Pricing/verification reflect Pallas Health's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on Pallas Health's site. Not medical advice; see our disclosure.

← Back to the scorecard